Incannex Healthcare Inc ADR (IXHL)

$0.60 -0.02 (-3.21%)
Market Cap 10.72M
Revenue (ttm) 10,000.00
Net Income (ttm) -18.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -184,600.00%
Debt to Equity Ratio 3.89
Volume 51,600
Avg Vol 161,978
Day's Range N/A - N/A
Shares Out 17.86M
Stochastic %K 14%
Beta 7.54
Analysts Strong Buy
Price Target N/A

Latest News on IXHL

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Apr 3, 2025, 7:30 AM EDT - 17 days ago

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

Mar 7, 2025, 2:10 PM EST - 6 weeks ago

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Feb 18, 2025, 5:51 PM EST - 2 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Feb 14, 2025, 7:30 AM EST - 2 months ago

Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

Feb 4, 2025, 9:15 AM EST - 2 months ago

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

Jan 23, 2025, 7:30 AM EST - 3 months ago

Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025

Dec 2, 2024, 4:48 PM EST - 4 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025

Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates

Nov 14, 2024, 4:05 PM EST - 5 months ago

Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

Oct 24, 2024, 7:30 AM EDT - 6 months ago

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)

Oct 2, 2024, 4:50 PM EDT - 7 months ago

Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

Sep 30, 2024, 4:01 PM EDT - 7 months ago

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives

Sep 9, 2024, 8:00 AM EDT - 7 months ago

Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed

Aug 5, 2024, 7:30 AM EDT - 9 months ago

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

Jul 30, 2024, 7:30 AM EDT - 9 months ago

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

May 30, 2024, 7:30 AM EDT - 11 months ago

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder

May 7, 2024, 7:30 AM EDT - 1 year ago

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder

Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)

May 1, 2024, 2:33 PM EDT - 1 year ago

Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

Feb 16, 2024, 7:30 AM EST - 1 year ago

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

Clarion Clinics Open for Psychedelic-Assisted Treatments

Feb 1, 2024, 7:30 AM EST - 1 year ago

Clarion Clinics Open for Psychedelic-Assisted Treatments

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Jan 24, 2024, 4:05 PM EST - 1 year ago

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences

Jan 18, 2024, 8:22 AM EST - 1 year ago

Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Jan 17, 2024, 7:30 AM EST - 1 year ago

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Dec 21, 2023, 4:05 PM EST - 1 year ago

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Dec 6, 2023, 7:30 AM EST - 1 year ago

Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Incannex Healthcare Announces Completion of its Redomiciliation to the United States

Nov 29, 2023, 1:40 PM EST - 1 year ago

Incannex Healthcare Announces Completion of its Redomiciliation to the United States

Federal Court of Australia Approves Incannex's Re-Domiciliation and Lodgement of Court Orders With ASIC

Nov 16, 2023, 8:30 AM EST - 1 year ago

Federal Court of Australia Approves Incannex's Re-Domiciliation and Lodgement of Court Orders With ASIC

Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023

Sep 8, 2023, 7:30 AM EDT - 1 year ago

Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023

Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD

Aug 24, 2023, 7:30 AM EDT - 1 year ago

Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD

Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed

Aug 22, 2023, 7:30 AM EDT - 1 year ago

Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed

Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening

Aug 8, 2023, 8:00 AM EDT - 1 year ago

Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening

Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement

Jul 28, 2023, 7:30 AM EDT - 1 year ago

Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement

Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

Jul 26, 2023, 7:30 AM EDT - 1 year ago

Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

Jul 21, 2023, 9:09 AM EDT - 1 year ago

Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea

Jul 18, 2023, 7:40 AM EDT - 1 year ago

Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea

Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq

Jul 10, 2023, 7:30 AM EDT - 1 year ago

Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq

Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company's Proprietary Drug for Treatment of Obstructive Sleep Apnoea (‘OSA')

Jul 6, 2023, 8:42 AM EDT - 1 year ago

Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company's Proprietary Drug for Treatment of Obstructive Sleep Apnoea (‘OSA')

Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023

Jun 23, 2023, 8:00 AM EDT - 1 year ago

Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023

Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

Jun 16, 2023, 8:00 AM EDT - 2 years ago

Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board

May 30, 2023, 8:00 AM EDT - 2 years ago

World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board

Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company

May 16, 2023, 7:50 AM EDT - 2 years ago

Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company

Incannex enters a lease for first psychedelic-assisted psychotherapy clinic

May 5, 2023, 7:30 AM EDT - 2 years ago

Incannex enters a lease for first psychedelic-assisted psychotherapy clinic

Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

May 3, 2023, 7:30 AM EDT - 2 years ago

Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A

May 2, 2023, 7:30 AM EDT - 2 years ago

Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A

Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU

Apr 14, 2023, 7:30 AM EDT - 2 years ago

Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU

Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts

Mar 16, 2023, 8:51 AM EDT - 2 years ago

Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts

Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment

Mar 15, 2023, 7:30 AM EDT - 2 years ago

Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment

Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use

Mar 3, 2023, 7:30 AM EST - 2 years ago

Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use

Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis

Feb 28, 2023, 7:25 AM EST - 2 years ago

Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis

Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases

Nov 29, 2022, 8:00 AM EST - 2 years ago

Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases

Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O

Nov 28, 2022, 8:00 AM EST - 2 years ago

Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O